MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1701/4619.46281

Медицинская библиотека · Recenti progressi in medicina · 2025

[Tafamidis between real-world evidence and registration trials: towards a price renegotiation with a view to sustainability and appropriateness].

Lupi Tiziano, Santoleri Fiorenzo, Belfiglio Maurizio

Аннотация на английскомСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The evolving epidemiological landscape of transthyretin amyloid cardiomyopathy (ATTR-CM), particularly in its wild-type form, highlights a progressive increase in diagnoses. This trend calls for a critical reflection on the economic sustainability of tafamidis treatment, given the expanding eligible patient population and the lack of price renegotiation.

METHODS

A retrospective study was conducted on patients treated at an Asl (2023-2025). Persistence and adherence to the treatment were evaluated. A linear regression model estimated future incidence and economic impact.

RESULTS

Among 17 patients, persistence was 58.82%, adherence (>80%) 100%. Incidence rose from 15.2 to 35.73 cases/million (2018-2025). The 5-year cost per patient exceeded € 815,000. Based on the ATTR-ACT trial NNT (7.46), 2.3 deaths may be prevented, though this benefit may be overestimated.

DISCUSSION: The rising incidence was not followed by a price revision. Use in older, frail patients and the absence of dynamic pricing agreements raise questions about cost-effectiveness and equitable access.

Для цитирования: Lupi Tiziano, Santoleri Fiorenzo, Belfiglio Maurizio. [Tafamidis between real-world evidence and registration trials: towards a price renegotiation with a view to sustainability and appropriateness].. Recenti progressi in medicina. 2025. DOI: 10.1701/4619.46281.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.